USING ANTIBODIES FOR TREATING AUTOIMMUNE DISEASES IN PATIENT WITH INADEQUATE RESPONSE TO TNF-ALPHA INHIBITOR

摘要

FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to rituximab binding to B-cell surface markers, e.g. CD20. More specifically, the invention concerns using rituximab for treating rheumatoid arthritis in a mammal with an inadequate response to a TNF-alpha inhibitor.EFFECT: invention provides reducing a joint damage in the patients.6 cl, 1 tbl, 1 ex